Company profile for Milestone Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Milestone is a clinical-stage drug development company developing novel small molecule therapeutics based on clinically-validated mechanisms of action for cardiovascular diseases. At its founding, the company assembled a panel of leading pharmaceutical R&D executives (“drug hunters”) each with an average of 30 years experience in drug development. These drug hunters proposed small molecule projects based on clinically-prov...
Milestone is a clinical-stage drug development company developing novel small molecule therapeutics based on clinically-validated mechanisms of action for cardiovascular diseases. At its founding, the company assembled a panel of leading pharmaceutical R&D executives (“drug hunters”) each with an average of 30 years experience in drug development. These drug hunters proposed small molecule projects based on clinically-proven science that became the foundation of Milestone’s drug development programs.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Canada
Address
Address
1111 Dr.-Frederik-Philips Blvd., Suite 420 Saint-Laurent, (Quebec) H4M 2X6 Can...
Telephone
Telephone
(514) 336-0444
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.biospace.com/fda/milestones-long-regulatory-road-ends-in-approval-for-cardamyst

BIOSPACE
15 Dec 2025

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218571

FDA
12 Dec 2025

https://www.globenewswire.com/news-release/2025/12/13/3204944/0/en/Milestone-Receives-FDA-Approval-of-CARDAMYST-etripamil-as-First-and-Only-Self-Administered-Nasal-Spray-for-Adults-with-Paroxysmal-Supraventricular-Tachycardia-PSVT.html

GLOBENEWSWIRE
12 Dec 2025

https://www.globenewswire.com/news-release/2025/11/12/3186091/0/en/Milestone-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Regulatory-and-Corporate-Update.html

GLOBENEWSWIRE
12 Nov 2025

https://www.globenewswire.com/news-release/2025/11/04/3180874/0/en/Milestone-Pharmaceuticals-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
04 Nov 2025

https://www.globenewswire.com/news-release/2025/11/03/3179176/0/en/Milestone-Pharmaceuticals-to-Present-New-Analysis-from-Investigational-Etripamil-Nasal-Spray-Clinical-Trials-for-PSVT-at-the-American-Heart-Association-Scientific-Sessions-2025.html

GLOBENEWSWIRE
03 Nov 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty